Used in scans for disrupted blood brain barrier and/or abnormal vascularity in the brain (intracranial lesions). ANDA 218749, held by Hainan Poly Pharm. Gadoteridol.
As of Nov 21, 2026, ANDA 218749 (Gadoteridol), held by Hainan Poly Pharm, was first approved by FDA on Feb 11, 2025, with 1 approved supplement and 0 published complete response letters.
Gadoteridol injection is a gadolinium-based contrast agent indicated for magnetic resonance imaging (MRI) to visualize: lesions with disrupted blood brain barrier and/or abnormal vascularity in the brain (intracranial lesions), spine and associated tissues in adults and pediatric patients, including term neonates lesions in the head and neck in adults 1.1 MRI of the Central Nervous System (CNS) Gadoteridol injection is indicated for magnetic resonance imaging (MRI) in adults and pediatric patients including term neonates to visualize lesions with disrupted blood brain barrier and/or abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 11, 2025 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Gadoteridol279.3MG/ML · injectable;injection | Gadoteridol | Rx |
| Aug 28, 2026 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 11, 2025 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters